KR880004814A - 이포스파미드 동결건조물 및 이의 제조방법 - Google Patents

이포스파미드 동결건조물 및 이의 제조방법 Download PDF

Info

Publication number
KR880004814A
KR880004814A KR870012077A KR870012077A KR880004814A KR 880004814 A KR880004814 A KR 880004814A KR 870012077 A KR870012077 A KR 870012077A KR 870012077 A KR870012077 A KR 870012077A KR 880004814 A KR880004814 A KR 880004814A
Authority
KR
South Korea
Prior art keywords
weight
phosphamide
ifosfamide
hexitol
parts
Prior art date
Application number
KR870012077A
Other languages
English (en)
Other versions
KR900003491B1 (ko
Inventor
자우에르비어 디이터
담만 우베-페터
이작 오토
Original Assignee
게르하르트 노바크,귄터 스타인메츠
아스타 파마 아크티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 게르하르트 노바크,귄터 스타인메츠, 아스타 파마 아크티엔게젤샤프트 filed Critical 게르하르트 노바크,귄터 스타인메츠
Publication of KR880004814A publication Critical patent/KR880004814A/ko
Application granted granted Critical
Publication of KR900003491B1 publication Critical patent/KR900003491B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cephalosporin Compounds (AREA)
  • Control Of El Displays (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Amplifiers (AREA)

Abstract

내용 없음

Description

이포스파미드 동결건조물 및 이의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (6)

  1. 이포스파미드(Ifosfamide), 이포스파미드 1중량부를 기준으로 하여 0.1 내지 17중량부의 헥시톨 및 임의로 다른 통상의 약제학적 보조물질을 함유하는 동결건조제제.
  2. 제1항에 있어서, 헥시톨이 만니톨임을 특징으로 하는 동결건조제제.
  3. 이포스파미드 1내지 13중량%, 이스파미드 1중량부를 기준으로 하여 헥시톨 0.1내지 17중량부 및, 임의로 이포스파미드 1중량부를 기준으로 하여 다른 약제학적 보조물질 0내지 16.9중량부를 함유하는 이포스파미드 수성 또는 수성-에탄올성 용액을 -70° 내지 0℃에서 동결시키고 ; 동결상태에서 이와 같이 수득한 생성물로부터 물을 제거함을 특징으로 하여, 이포스파미드 동결건조물을 제조하는 방법.
  4. 제3항에 있어서, 초기에 비-흡수성 결합수를 -30 내지 40℃의 온도 및 10-3내지 10mbar의 압력에서 먼저 제거하고 ; 이어서 흡수성 결합수를 0내지 40℃의 온도 및 10-4내지 10-1mbar의 압력에서 제거함을 특징으로 하는 방법.
  5. 제3 또는 4항에 있어서, 핵시톨이 만니톨임을 특징으로 하는 방법.
  6. 제3 내지 5항중 어느 한 항에 따라 수득한 이포스파미드 동결건조물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019870012077A 1986-10-31 1987-10-30 이포스파미드 동결건조물 및 이의 제조방법 KR900003491B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3637089 1986-10-31
DEP3637089.4 1986-10-31

Publications (2)

Publication Number Publication Date
KR880004814A true KR880004814A (ko) 1988-06-27
KR900003491B1 KR900003491B1 (ko) 1990-05-21

Family

ID=6312873

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019870012077A KR900003491B1 (ko) 1986-10-31 1987-10-30 이포스파미드 동결건조물 및 이의 제조방법

Country Status (25)

Country Link
EP (1) EP0265812B1 (ko)
JP (1) JPS63159319A (ko)
KR (1) KR900003491B1 (ko)
AT (1) ATE55250T1 (ko)
AU (1) AU598602B2 (ko)
CA (1) CA1314231C (ko)
DD (1) DD262582A5 (ko)
DE (1) DE3764235D1 (ko)
DK (1) DK169308B1 (ko)
EG (1) EG18333A (ko)
ES (1) ES2017982B3 (ko)
FI (1) FI87140C (ko)
GE (1) GEP19971025B (ko)
GR (1) GR3000708T3 (ko)
HU (1) HU197987B (ko)
IL (1) IL84312A (ko)
IN (1) IN168119B (ko)
LV (1) LV10051B (ko)
MX (1) MX8958A (ko)
NO (1) NO873860L (ko)
PT (1) PT86032B (ko)
RU (1) RU1836079C (ko)
UA (1) UA11075A (ko)
YU (1) YU197387A (ko)
ZA (1) ZA878183B (ko)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE58900183D1 (de) * 1988-03-19 1991-08-29 Asta Pharma Ag Ifosfamid-mesna-lyophilisat und verfahren zu dessen herstellung.
US5227373A (en) * 1991-10-23 1993-07-13 Bristol-Myers Squibb Co. Lyophilized ifosfamide compositions
WO1995007083A1 (en) * 1993-09-10 1995-03-16 F.H. Faulding & Co. Limited Ifosfamide lyophilisate composition
DE19529057B4 (de) * 1995-08-08 2007-12-13 Baxter Healthcare S.A. Ifosfamid-Lyophilisat-Zubereitungen
JP2002505282A (ja) * 1998-03-03 2002-02-19 塩野義製薬株式会社 ホスホリパーゼ阻害剤の［［３−（２−アミノ−１，２−ジオキソエチル）−２−エチル−１−フェニルメチル）−１ｈ−インドール−４−イル］オキシ］酢酸ナトリウムを含む薬学的組成物
NZ538584A (en) * 2002-09-05 2007-05-31 Bharat Serums & Vaccines Ltd Stable liquid composition of oxazaphosphorine, mesna and etherified beta-cyclodextrin
MXPA05005919A (es) * 2002-12-02 2005-09-21 Bharat Serums & Vaccines Ltd Composiciones de ifosfamida para la administracion parenteral, y un proceso para su preparacion.
US8436190B2 (en) * 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
JP5619419B2 (ja) * 2006-09-29 2014-11-05 インファ ソシエテ アノニム 薬学的組成物用調剤システム及び静脈内投与用キット
WO2016087001A1 (en) * 2014-12-04 2016-06-09 Huawei Technologies Co., Ltd. Load allocation in a data communication network

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3732340A (en) * 1966-07-11 1973-05-08 Asta Werke Ag Chem Fab N',o-propylene phosphoric acid ester diamides
DE2750207A1 (de) * 1977-05-09 1978-11-16 Walton J Smith Gefriergetrocknete zusammensetzungen, insbesondere gefriergetrocknete pharmazeutische praeparate und verfahren zu deren herstellung
EP0083439B1 (de) * 1981-12-31 1989-07-26 ASTA Pharma AG 4-Sulfido-oxazaphosphorine und deren Verwendung bei der Krebsbekämpfung und zur Immunsuppression
US4537883A (en) * 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide

Also Published As

Publication number Publication date
ES2017982B3 (es) 1991-03-16
DD262582A5 (de) 1988-12-07
RU1836079C (ru) 1993-08-23
DK569687A (da) 1988-05-01
KR900003491B1 (ko) 1990-05-21
MX8958A (es) 1993-12-01
FI874727A (fi) 1988-05-01
JPS63159319A (ja) 1988-07-02
HU197987B (en) 1989-07-28
FI87140C (fi) 1992-12-10
IL84312A0 (en) 1988-03-31
JPH0543684B2 (ko) 1993-07-02
LV10051B (en) 1995-06-20
EP0265812B1 (de) 1990-08-08
DE3764235D1 (de) 1990-09-13
DK569687D0 (da) 1987-10-30
IN168119B (ko) 1991-02-09
LV10051A (lv) 1994-05-10
NO873860L (no) 1988-05-02
DK169308B1 (da) 1994-10-10
UA11075A (uk) 1996-12-25
FI87140B (fi) 1992-08-31
FI874727A0 (fi) 1987-10-27
NO873860D0 (no) 1987-09-15
ZA878183B (en) 1988-05-02
PT86032A (de) 1987-11-01
GR3000708T3 (en) 1991-10-10
YU197387A (en) 1988-12-31
IL84312A (en) 1991-11-21
AU598602B2 (en) 1990-06-28
EP0265812A1 (de) 1988-05-04
GEP19971025B (en) 1997-04-06
HUT44932A (en) 1988-05-30
CA1314231C (en) 1993-03-09
PT86032B (pt) 1990-08-31
AU8052987A (en) 1988-05-05
ATE55250T1 (de) 1990-08-15
EG18333A (en) 1993-12-30

Similar Documents

Publication Publication Date Title
ATE81284T1 (de) Lyophilisierter schaum.
US5044091B1 (en) Method of preparing a freeze-dried formulation of a drug
EP0290616A4 (en) GAMMA RAY STERILIZATION PROCESS FOR POLYVINYL ALCOHOL GEL.
ATE103914T1 (de) Neue thienylcarbonsaeureester von aminoalkoholen, ihre quaternierungsprodukte sowie die herstellung und verwendung dieser verbindungen.
KR880004814A (ko) 이포스파미드 동결건조물 및 이의 제조방법
SE8403487L (sv) Farmaceutisk komposition
KR930007453A (ko) 동결건조 이포스파미드 조성물
DE3766200D1 (de) L-dopa enthaltendes arzneimittel.
FR2601259B1 (fr) Nouvelles compositions tensio-actives a base d'esters phosphoriques leur procede de preparation et leur application a la formulation de matieres actives.
CA2067381A1 (en) Treatment of hiv infections and compounds useful therein
GR3002377T3 (en) Ifosfamide-mesna-lyophilized composition and process to prepare it
ES522637A0 (es) Procedimiento para la preparacion de nuevas sustancias ws 6049.
KR850001687A (ko) 안정화 항균성 동결 건조제제
IE43125L (en) Aminoglycoside derivative
KR890012960A (ko) 결정성 β-락탐 용매화물
FR2401162A1 (fr) Antibiotique derive d'un streptomyces, utilisable comme medicament
KR930003910A (ko) 파라세타몰의 생체이용율을 높이는 방법 및 이 생체이용율이 높아진 파라세타몰을 함유한 제제
EP0297523A3 (de) Verfahren zur Herstellung von Elaiophylin und dessen Verwendung
HUT44802A (en) Process for producing pseudo-oligosaccharides and pharmaceutical compositions containing them
IE36183L (en) Pepstatins
SU565653A1 (ru) Способ консервировани костной ткани
KR910015294A (ko) 약제 조성물
BE788899A (fr) Procede de preparation de derives de benzodiazepine-1,4 one-2 utiles notamment comme agents tranquillisants et sedatifs
JPS5679626A (en) Semi-solid medicine
IE38489L (en) Process for obtaining d-penicillamine

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20070517

Year of fee payment: 18

EXPY Expiration of term